These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 24173819)

  • 1. Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation.
    Döring M; Blume O; Haufe S; Hartmann U; Kimmig A; Schwarze CP; Lang P; Handgretinger R; Müller I
    Eur J Clin Microbiol Infect Dis; 2014 Apr; 33(4):629-38. PubMed ID: 24173819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
    Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.
    Döring M; Müller C; Johann PD; Erbacher A; Kimmig A; Schwarze CP; Lang P; Handgretinger R; Müller I
    BMC Infect Dis; 2012 Oct; 12():263. PubMed ID: 23082876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.
    Döring M; Eikemeier M; Cabanillas Stanchi KM; Hartmann U; Ebinger M; Schwarze CP; Schulz A; Handgretinger R; Müller I
    Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1189-200. PubMed ID: 25680318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.
    Marks DI; Pagliuca A; Kibbler CC; Glasmacher A; Heussel CP; Kantecki M; Miller PJ; Ribaud P; Schlamm HT; Solano C; Cook G;
    Br J Haematol; 2011 Nov; 155(3):318-27. PubMed ID: 21880032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
    Solano C; Slavin M; Shaul AJ; Marks DI; Cordonnier C; Cornely OA; Pagliuca A; Cragin L; Jarque I; Garcia-Vidal C; Sorensen S; Vanness DJ; Charbonneau C; Barrueta JA; Peral C; De Salas-Cansado M; Bow EJ
    Mycoses; 2017 Feb; 60(2):79-88. PubMed ID: 27562016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
    Ziakas PD; Kourbeti IS; Mylonakis E
    Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
    Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
    J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.
    Lin R; Xu X; Li Y; Sun J; Fan Z; Jiang Q; Huang F; Zhou H; Nie D; Guo Z; Mao Y; Xiao Y; Liu Q
    Transpl Infect Dis; 2014 Apr; 16(2):286-94. PubMed ID: 24593273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation.
    Sánchez-Ortega I; Patiño B; Muñoz C; Arnan M; Peralta T; Clopés A; de Sevilla AF; Duarte RF
    J Med Econ; 2013; 16(6):736-43. PubMed ID: 23541251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.
    Ananda-Rajah MR; Grigg A; Downey MT; Bajel A; Spelman T; Cheng A; Thursky KT; Vincent J; Slavin MA
    Haematologica; 2012 Mar; 97(3):459-63. PubMed ID: 22058198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
    Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis.
    Wang J; Zhou M; Xu JY; Zhou RF; Chen B; Wan Y
    JAMA Netw Open; 2020 Oct; 3(10):e2017652. PubMed ID: 33030550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients.
    Lehrnbecher T; Fisher BT; Phillips B; Beauchemin M; Carlesse F; Castagnola E; Duong N; Dupuis LL; Fioravantti V; Groll AH; Haeusler GM; Roilides E; Science M; Steinbach WJ; Tissing W; Warris A; Patel P; Robinson PD; Sung L
    J Clin Oncol; 2020 Sep; 38(27):3205-3216. PubMed ID: 32459599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label trial of the prophylactic administration of voriconazole in patients who undergo allogeneic hematopoietic stem cell transplantation: study protocol.
    Kunitomi A; Hasegawa Y; Hashimoto H; Saito AM; Iida H
    Nagoya J Med Sci; 2018 Nov; 80(4):591-595. PubMed ID: 30587873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study.
    Ye P; Pei R; Hu Y; Chen D; Li S; Cao J; Li F; Wu M; Fang Y; Lu Y
    BMC Infect Dis; 2022 May; 22(1):465. PubMed ID: 35570276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation.
    Chaftari AM; Hachem RY; Ramos E; Kassis C; Campo M; Jiang Y; Prince RA; Wang W; Raad II
    Transplantation; 2012 Aug; 94(3):302-8. PubMed ID: 22814329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis.
    Zhao YJ; Khoo AL; Tan G; Teng M; Tee C; Tan BH; Ong B; Lim BP; Chai LY
    Antimicrob Agents Chemother; 2016 Jan; 60(1):376-86. PubMed ID: 26525782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
    Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
    J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.